Vandetanib Moderately Active in RET+ Advanced NSCLC

Share this content:
An oncologist reviews test results.
An oncologist reviews test results.

Vandetanib possesses moderate activity in pretreated patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor RET rearrangements, a study published in the journal Annals of Oncology has shown.1

Approximately 1% of NSCLC tumors have chromosomal rearrangements involving RET. Vandetanib is a kinase inhibitor of VEGFR, EGFR, and the RET-tyrosine kinase. Therefore, researchers sought to evaluate the efficacy and safety of vandetanib in this patient population.

For the multicenter, open-label, phase 2 study ( Identifier: NCT01823068), investigators enrolled 18 patients with metastatic or recurrent NSCLC and a RET rearrangement who had progressive disease after platinum-based doublet chemotherapy and a performance status of 0 to 2.

Among the 17 evaluable patients, results showed that 3 achieved a partial response and 8 had stable disease. The objective response rate was 18% and the disease control rate was 65%. The response or disease stabilization lasted for longer than 6 months in 8 patients.

After a median follow-up of 14 months, researchers also found that median progression-free survival and median overall survival were 4.5 months and 11.6 months, respectively.

The most common adverse events were hypertension and rash, occurring in more than 70% of patients. Most cases were mild. Four patients required dose reductions and 5 patients experienced grade 3 toxicities. No grade 4 or 5 adverse events were observed.


1. Lee SH, Lee JK, Ahn MJ, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer harboring RET rearrangement: A phase II clinical trial. Ann Oncol. 2016 Nov 1. doi: 10.1093/annonc/mdw559. [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs